CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $87.4 million in its first quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.98.
The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.83 per share.
The cancer drug developer posted revenue of $730,000 in the period.
Blueprint Medicines shares have climbed 42% since the beginning of the year. The stock has decreased 2% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC